Technical Analysis for XENE - Xenon Pharmaceuticals Inc.

Grade Last Price % Change Price Change
D 39.97 1.60% 0.63
XENE closed up 1.26 percent on Wednesday, November 20, 2024, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 1.60%
Lower Bollinger Band Walk Weakness 1.60%
Oversold Stochastic Weakness 1.60%
Lower Bollinger Band Walk Weakness 2.88%
Inside Day Range Contraction 2.88%
Lower Bollinger Band Touch Weakness 2.88%
Oversold Stochastic Weakness 2.88%
MACD Bearish Centerline Cross Bearish 4.33%
Lower Bollinger Band Walk Weakness 4.33%
Multiple of Ten Bearish Other 4.33%

   Recent Intraday Alerts

Alert Time
Up 2% about 1 hour ago
60 Minute Opening Range Breakout about 1 hour ago
Rose Above Previous Day's High about 2 hours ago
Down 1% about 2 hours ago
Up 1% about 2 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Xenon Pharmaceuticals Inc. Description

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is engaged in discovering and developing therapeutics for orphan indications. The company offers Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Its product candidates in development comprise TV-45070, which is in Phase IIb clinical trials for the treatment of osteoarthritis of the knee; and in Phase II proof-of-concept clinical trials for the treatment of postherpetic neuralgia and Erythromelalgia. It is also developing TV-45070 for neuropathic pain indications; and GDC-0276 for the treatment of pain. The company's preclinical product candidates include a sodium channel inhibitor to treat DRAVET SYNDROME, an orphan disorder; XEN801, a stearoyl Co-A desaturase, an inhibitor for the treatment of acne; and small-molecule inhibitors for the treatment of cardiovascular disease. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd., Genentech, Inc., and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Organic Compounds Chemical Compounds Gene Therapy Cardiovascular Disease Analgesics Osteoarthritis Knee Acne Pharmaceutical Industries Lipoprotein Neuropathic Pain Treatment Of Osteoarthritis Teva Pharmaceutical Industries Treatment Of Cardiovascular Disease Alipogene Tiparvovec Erythromelalgia Glybera Lipase Lipoprotein Lipase Deficiency Postherpetic Neuralgia

Is XENE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 50.99
52 Week Low 28.2005
Average Volume 346,685
200-Day Moving Average 41.56
50-Day Moving Average 41.21
20-Day Moving Average 42.00
10-Day Moving Average 41.83
Average True Range 1.59
RSI (14) 39.76
ADX 19.55
+DI 16.25
-DI 31.54
Chandelier Exit (Long, 3 ATRs) 41.24
Chandelier Exit (Short, 3 ATRs) 42.14
Upper Bollinger Bands 45.90
Lower Bollinger Band 38.10
Percent B (%b) 0.16
BandWidth 18.59
MACD Line -0.49
MACD Signal Line 0.13
MACD Histogram -0.6196
Fundamentals Value
Market Cap 2.96 Billion
Num Shares 75.3 Million
EPS -2.66
Price-to-Earnings (P/E) Ratio -14.79
Price-to-Sales 181.44
Price-to-Book 5.92
PEG Ratio -0.06
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 41.08
Resistance 3 (R3) 40.92 40.19 40.79
Resistance 2 (R2) 40.19 39.74 40.27 40.69
Resistance 1 (R1) 39.76 39.47 39.98 39.92 40.60
Pivot Point 39.03 39.03 39.13 39.11 39.03
Support 1 (S1) 38.60 38.58 38.82 38.76 38.08
Support 2 (S2) 37.87 38.31 37.95 37.99
Support 3 (S3) 37.44 37.87 37.89
Support 4 (S4) 37.60